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Abstract
In August 2012, the Brazilian Ministry of Health introduced inactivated polio vaccine (IPV) as 
part of sequential polio vaccination schedule for all infants beginning their primary vaccination 
series. The revised childhood immunization schedule included 2 doses of IPV at 2 and 4 months of 
age followed by 2 doses of oral polio vaccine (OPV) at 6 and 15 months of age. One annual 
national polio immunization day was maintained to provide OPV to all children aged 6 to 59 
months. The decision to introduce IPV was based on preventing rare cases of vaccine-associated 
paralytic polio, financially sustaining IPV introduction, ensuring equitable access to IPV, and 
preparing for future OPV cessation following global eradication. Introducing IPV during a 
national multivaccination campaign led to rapid uptake, despite challenges with local vaccine 
supply due to high wastage rates. Continuous monitoring is required to achieve high coverage with 
the sequential polio vaccine schedule.
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The World Health Organization (WHO) recommends that all children worldwide be 
immunized against polio and that all countries achieve and maintain high levels of coverage 
with polio vaccine [1]. Until global polio eradication is achieved, WHO and the Pan 
American Health Organization (PAHO) guidance for national policy on polio immunization 
is based on evaluation of the potential for wild poliovirus (WPV) importation and 
transmission [1, 2]. Important factors include risk of WPV importations resulting from 
international travel, polio vaccination coverage, quality of surveillance for acute flaccid 
paralysis (AFP), sanitation, and socioeconomic conditions [1]. In the pre-eradication period, 
WHO recommends inactivated polio vaccine (IPV) as an alternative to oral polio vaccine 
(OPV) only in countries that have the lowest risk of both WPV importation and transmission 
[1]. In countries that do not achieve homogeneous vaccination coverage of 95% or greater in 
every district, PAHO recommends conducting annual polio vaccination campaigns targeting 
all children <5 years of age regardless of prior vaccination status [2].
Brazil is an upper-middle-income country in South America with a population of 199 
million and approximately 3 million annual births. Since its creation in 1973, Brazil’s 
National Immunization Program has exclusively used OPV for routine infant immunizations 
and supplemental immunization activities (SIAs) [3]. Use of OPV successfully interrupted 
transmission of wild poliovirus in Brazil and eliminated polio from the Americas. Brazil has 
maintained high polio vaccination coverage nationwide since polio elimination, although 
heterogeneous vaccination coverage may leave pockets of individuals susceptible to WPV 
infection in the event of a WPV importation.
In August 2012, the Brazilian Ministry of Health introduced inactivated polio vaccine (IPV) 
as part of sequential IPV-OPV vaccination, including 2 doses of IPV at 2 and 4 months of 
age followed by 2 doses of trivalent OPV at 6 and 15 months of age for all infants beginning 
their primary vaccination series [4]. A sequential IPV-OPV schedule was chosen to prevent 
vaccine-associated paralytic poliomyelitis (VAPP) and provide mucosal immunity to reduce 
the potential for transmission of wild or vaccine-derived polioviruses (VDPVs). With the 
introduction of the sequential IPV-OPV schedule, the Ministry of Health revised the strategy 
for National Polio Immunization Days to conduct a single round of polio vaccination, during 
the month of June, offering OPV to all children aged 6 to 59 months regardless of prior 
polio vaccination status [4]. The introduction of a sequential IPV-OPV schedule and 
transition to a single supplemental polio immunization day were seen as preparatory steps 
for a posteradication polio vaccination strategy in Brazil. Here we review considerations for 
IPV introduction in Brazil’s National Immunization Program and describe early uptake of 
IPV.
BRIEF HISTORY OF POLIO VACCINATION IN BRAZIL, 1961–2012
Polio vaccination with OPV began in the early 1960s in response to polio outbreaks [5]. 
OPV was one of the recommended routine childhood vaccines when the National 
Immunization Program was created in 1973 (Table 1), although coverage with 3 doses of 
OPV among children aged <1 year reached only 51% in 1979 [5]. From 1971 to 1973, 
nationally coordinated mass vaccination campaigns were conducted in most states and 
resulted in dramatic declines in polio incidence [5]. Discontinuation of mass campaigns in 
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1974 led to resurgence in polio cases, which peaked in 1979 and resulted in institution of 
biannual national polio immunization days (NIDs) in 1980 [5–7]. The objective of polio 
NIDs was to vaccinate all children aged <5 years with OPV, regardless of prior vaccination 
history. NIDs played an important role in polio elimination in Brazil and the Americas [7]. 
The last confirmed case of wild poliovirus in Brazil occurred in 1989, followed by the last 
case in the Americas in 1991. WHO certified polio elimination from Brazil and the 
Americas in 1994 [8, 9].
Investigations of polio outbreaks in Brazil and serologic studies helped identify factors that 
influenced immunogenicity of OPV and led to changes in the OPV formulation adopted for 
the Global Polio Eradication Initiative [10–13]. In addition, research in Brazil on IPV in the 
1980s identified potential advantages of IPV for routine immunization, including higher 
seroconversion rates and prevention of VAPP, while OPV was preferable for mass 
vaccination [14].
CONSIDERATIONS FOR IPV INTRODUCTION
Prior to IPV introduction into Brazil’s childhood immunization schedule, revision of the 
national polio vaccination policy was discussed at multiple meetings of the national 
technical advisory committee on immunizations, composed of immunization experts and 
representatives of professional societies. Considerations included risk of WPV importation, 
vaccine safety, sustainability, equity, vaccination strategies, and optimal schedule. In 2008, 
the National Immunization Program began developing a plan for IPV introduction through 
routine immunization services. The main components of the revised polio vaccination policy 
included use of a sequential IPV-OPV schedule, continuation of polio vaccination strategies 
(NIDs and routine vaccination) until global polio eradication, and sustainability of polio 
vaccination in the recommended childhood immunization schedule.
Potential for WPV Importation and Transmission
As long as wild poliovirus circulates anywhere in the world, all polio-free countries are at 
risk for WPV importation [1]; countries immediately bordering endemic countries and those 
with low routine immunization coverage are at highest risk [1]. Transmission potential 
following an importation is also higher in tropical countries with suboptimal sanitation [1]. 
Brazil has not had any WPV importations since certification of elimination, and all reported 
cases of paralytic poliomyelitis in the Americas have been caused by vaccine viruses or 
VDPVs [15]. However, importations of WPV into polio-free countries have occurred as a 
result of international air travel [16], and previously polio-free regions have experienced 
extensive outbreaks resulting from WPV importation [17].
Routine coverage with 3 doses of OPV (OPV3) in Brazilian infants, based on administrative 
data, has been maintained above 95% nationally since 2000 (Table 2). Due to the limitations 
of administrative data to monitor immunization coverage at the municipal level, state and 
municipal immunization programs increasingly use rapid coverage monitoring (used in large 
scale following mass measles-rubella vaccination in 2008 [18]) to identify undervaccinated 
populations. A survey of children in state capital cities showed high OPV3 coverage at all 
socioeconomic levels [19]. In addition, introduction of a national immunization registry in 
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2012 will eventually provide more accurate estimates of vaccination coverage and reduce 
the reliance on administrative data [20].
Between 1970 and 2010, indicators of sanitation infrastructure and socioeconomic 
conditions improved dramatically in Brazil [21]. However, sanitation, development, and 
immunization coverage are heterogeneously distributed throughout Brazil, and a large 
number of municipalities report less than 95% coverage with OPV3, especially in tropical 
areas (Figure 1). In these areas, continued OPV use in routine immunizations and SIAs 
provides advantages for boosting mucosal immunity, facilitating administration in remote 
areas, and providing herd immunity through secondary spread of vaccine viruses.
Prevention of VAPP
Prevention of VAPP and risk of VDPVs in immunocompromised children, despite their rare 
occurrence, was considered important for maintaining public confidence in the national 
immunization program. Reported incidence of VAPP in Brazil of 1 case per 10.7–13 million 
OPV doses administered (or 1 case per 2.4–5.1 million first OPV doses) [22, 23] was lower 
than estimates from the United States (2.5 cases per million OPV doses administered or 0.7 
cases per million first OPV doses) [24], raising concerns about completeness of VAPP 
ascertainment in Brazil.
Limitations of Surveillance
In Brazil, AFP surveillance is conducted by state and municipal health departments and 
coordinated by the Secretariat for Health Surveillance of the Ministry of Health. While the 
main objective of AFP surveillance is early detection of WPV importation, it is also 
essential for detection of vaccine-associated cases and VDPVs. All cases of AFP in 
individuals younger than 15 years, as well as any suspected poliomyelitis case in individuals 
of any age with travel history in the previous 30 days to countries with circulation of WPV, 
must be reported to state and municipal health departments, investigated immediately, and 
entered into the national surveillance system for notifiable diseases [Sistema de Informação 
de Agravos de Notificação (Sinan)]. Follow up includes examination of neurological 
function and laboratory examination of stool specimens (ideally collected within 14 days of 
onset of paralysis).
Review of AFP surveillance indicators highlighted the need for maintaining surveillance 
quality and timeliness of diagnosis of AFP cases to rapidly detect and respond to poliovirus 
importations [25]. During 2003–2012, the national nonpolio AFP reporting rate was slightly 
above 1.0 case per 100 000 population aged <15 years, PAHO’s target reporting rate for 
AFP surveillance in the Americas (Table 3). However, fewer than 80% of reported cases had 
collection of adequate stool specimens, falling below the target indicator. Maintaining 
surveillance quality is challenging and requires coordination between health professionals, 
surveillance officers, laboratory staff, and directors of the Unified Health System (SUS) at 
all levels.
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From 1980 to 2011, Brazil held biannual NIDs (usually in June and August) for all children 
under 5 years of age, regardless of prior immunization status. With the introduction of the 
sequential IPV-OPV schedule, the National Immunization Program maintained 1 annual 
NID (in June) with OPV, targeting children aged 6–59 months, regardless of prior 
immunization status. The previous NID in August was replaced with a multivaccination 
campaign to provide children up to their fifth birthday with missing vaccinations and to 
update child health cards.
The decision to replace 1 NID day with a multivaccination campaign was based on potential 
benefits of social mobilization to improve routine immunization coverage and complete 
vaccination schedules. In the 1980s, Brazil’s National Immunization Program encouraged 
the use of NIDs to provide opportunities for “catch-up” vaccination of children missing 
recommended doses, as long as multivaccination did not have a negative impact on 
vaccination against poliomyelitis [26]. The decision regarding which antigens to offer 
during NIDs was left up to state and municipal immunization programs. An immunization 
survey of children born in 2005 showed that 15% had received recommended vaccines 
needed to complete immunization schedules during the most recent NID [26].
Revision of Recommended Childhood Immunization Schedule
IPV introduction was part of a revision of the childhood immunization calendar in 2012 
(Table 4), including the sequential IPV-OPV schedule and 3 doses of pentavalent DTwP–
Haemophilus influenzae type b conjugate-recombinant hepatitisvaccine (pentavalent 
vaccine, Bio-Manguinhos Institute, Rio de Janeiro, Brazil and Butantan Institute, São Paulo, 
Brazil). Pentavalent vaccine replaced quadrivalent DTwP-Hib vaccine and eliminated the 
need for 2 injections of monovalent hepatitisvaccine to complete the primary 
hepatitisschedule (previously recommended at birth, 1 month, and 6 months of age). The 
birth dose of monovalent hepatitisvaccine was maintained for the prevention of vertical 
transmission. Launching the sequential IPV-OPV schedule with pentavalent vaccine 
introduction (replacing separate injections of hepatitis and DTwP-Hib vaccines) resulted in 
the same number of injections a child would receive to complete the recommended 
immunization schedule.
An interval of 60 days was recommended between the first and second IPV doses, as well as 
between the second IPV dose and the first OPV dose in the sequential series. During the first 
6 months of life, a minimum interval between doses of 30 days was recommended for 
infants traveling to endemic countries or at risk of exposure to WPV. Additional guidance 
was provided for vaccination of children who had received OPV or for whom OPV was not 
recommended (Table 5).
Equity
The additional cost of IPV was compared with introduction of new vaccines and increases in 
the National Immunization Program budget [20]. Equity was an important consideration, as 
IPV became recommended by professional societies [27], while children of higher 
socioeconomic status were more likely to receive IPV in the private sector [19] and less 
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likely to receive OPV during NIDs [26]. In the public sector, IPV had been recommended 
for specific groups of children for whom OPV was contraindicated and was provided at 
specialized vaccine reference centers (CRIE, for the acronym in Portuguese) since 1993 
[28]. Increased referral of children to specialized reference centers for IPV resulted in a 
jump in IPV doses administered from 20 145 in 2008 to 37 305 in 2010.
Sustainability
In 2010, the Science and Technology Secretariat of the Ministry of Health, together with 
public vaccine manufacturer Bio-Manguinhos Institute, Rio de Janeiro, developed technical 
guidelines for incorporating standalone IPV or IPV-containing combination vaccines into 
the National Immunization Program, considering options of international purchase, national 
production, or acquisition of technology for national production. These technical guidelines 
estimated costs of IPV introduction, as well as mapping strategies to achieve sustainable 
IPV use in Brazil.
To comply with national legislation requiring self-sustainability in vaccine production as 
well as international regulations on IPV manufacture, Brazil’s Ministry of Health and Bio-
Manguinhos Institute signed an agreement with Sanofi Pasteur to supply IPV types 1, 2, and 
3 for formulation and distribution in Brazil after 2012. Bio-Manguinhos Institute would also 
begin evaluating combination products, including imported IPV and domestically produced 
DTwP, hepatitis(HepB), and H. influenzae type b (Hib) antigens for future use in Brazil.
EARLY UPTAKE OF IPV
Beginning with the national multivaccination campaign in August 2012, IPV was 
administered to children at 2 months of age (60 days), initiating the primary immunization 
series with pentavalent DTwP-Hib-HepB, pneumococcal conjugate vaccine, and oral 
rotavirus vaccine. Vaccination histories of children aged <5 years documented in child 
health cards were evaluated by health workers at fixed vaccination posts in health facilities 
or mobile posts that functioned during the campaign. Vaccination series were initiated in 
previously unvaccinated children and those without documented vaccination history. 
Immunizations offered included all vaccines in the recommended childhood vaccination 
calendar of the National Immunization Program. Vaccination was selective, based on 
evaluation of each child’s vaccination history. IPV and pentavalent DTwP-Hib-HepB 
vaccines were administered according to the revised childhood vaccination schedule.
The 2012 national multivaccination campaign was organized along the same principles as an 
NID to expand access to vaccines by providing immunizations at a large number of fixed 
and mobile vaccine posts, as well as through outreach. The multivaccination campaign was 
conducted over a 7-day period from 18 to 24 August and involved approximately 350 000 
health workers at 115 000 vaccination posts (including approximately 30 000 permanent 
vaccination posts at health facilities) and 40 000 vehicles. Federal funding for the campaign 
was the same as for the national polio immunization day (18.6 million reais [US $9.3 
million]) in addition to contributions from state and municipal health departments.
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Administrative Estimates of IPV Coverage
Brazil has an annual birth cohort of approximately 2.8 million surviving infants. In 2012, the 
monthly vaccination target (based on registered live births in 2011) was 240 006 children 
aged <1 year for each vaccine dose recommended in the first year of life. During the initial 
multivaccination campaign from 18 to 24 August 2012, a total of 114 803 IPV doses were 
administered to children aged <1 year (Table 6); 102 784 were registered as first doses and 
12 019 as second doses for children who received IPV in the private sector or had medical 
indications for receipt of IPV at the Ministry of Health’s CRIE. In routine immunization 
services, a total of 770 942 first IPV doses were administered from September to December 
2012, reaching 80% of the quarterly target of 960 024 doses among children aged <1 year 
nationally and >95% of the quarterly target in 2658 (48%) of 5564 municipalities (Figure 
1B), while 319 579 second doses were administered in November and December, reaching 
67% of the target population (Table 6).
Vaccine Supply
Standalone IPV was included in the children’s immunization calendar in 2012. A total of 11 
million doses of standalone IPV in 10-dose vials were purchased in 2012 at a cost of 55 
million reais (approximately US $26 million in 2012). Although the 10-dose presentation of 
IPV includes 2-phenoxyethanol as a preservative, vials were to be discarded 6 hours after 
opening. IPV vaccination occurred simultaneously in all states and the federal district.
During the first months of IPV use, immunization programs reported substantially increased 
vaccine wastage due to requirements to discard opened vials after 6 hours. Unexpectedly 
high wastage resulted in IPV stock-outs in some health centers, requiring constant 
management and redistribution of available vaccine to avoid running out of IPV over larger 
areas. In cases of IPV stock-outs at health centers, the National Immunization Program 
advised rescheduling children to maintain sequential IPV-OPV schedules rather than 
returning to an OPV-only schedule. In November 2012, Brazil’s national regulatory 
authority approved a label change, permitting the use of 10-dose vials for 7 days after 
opening. The label change reduced IPV wastage and resolved problems with vaccine supply.
Surveillance for Adverse Events Following Immunization
IPV is well tolerated and has not been associated with severe adverse events [29]. Based on 
reported rates of adverse events following immunization (AEFI), mild, local reactions were 
expected in a small proportion of vaccinees, including erythema at the injection site (<3%), 
induration (<12%), and tenderness (<30%). Reporting of systemic reactions (such as fever) 
and other AEFIs associated with any of the vaccines coadministered with IPV, including 
DTwP-Hib-HepB, oral rotavirus, and pneumococcal conjugate vaccine, was expected in 
infants who had received IPV. Immunization providers were also alerted to the possibility of 
hypersensitivity reactions in infants due to the presence in the IPV formulation of trace 
amounts of the antibiotics streptomycin, neomycin, and polymyxin B. Following IPV 
introduction, no increase was observed in rates of reported AEFIs, including fever, 
convulsions, and hypotonic-hyporesponsive episodes (data not shown). A single AEFI 
(classified as a moderate local reaction) was reported in an infant who received IPV with no 
concomitant injections.
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Communication strategies for the multivaccination campaign targeted 2 main audiences: 
information for healthcare workers, professional societies, and opinion leaders provided 
rationale for the new vaccination schedule; while public messages encouraged parents to 
take children younger than 5 years of age to an immunization post during the campaign to 
review the child’s vaccinations, even if the child was considered “up to date.” Messages 
emphasized prevention of vaccine-preventable diseases, as well as the introduction of 2 new 
vaccines (pentavalent vaccine and IPV). Prior to IPV introduction, state and municipal 
immunization programs conducted trainings for healthcare professionals on the sequential 
IPV-OPV schedule; high acceptance of IPV, and the revised immunization calendar was 
reported. As in other vaccination campaigns, the Brazilian Minister of Health held a press 
conference prior to the campaign launch to explain the objectives of the multivaccination 
campaign to the media, reaching a broad audience. Social networks and electronic media 
were also used as in previous campaigns to provide information on vaccination activities 
[30].
DISCUSSION
Brazil is one of a growing number of countries that have introduced IPV in national 
immunization programs [15, 31]. As of December 2012, 66 WHO member states included 
IPV in national immunization programs, including 7 in the Americas (Bahamas, Brazil, 
Canada, Costa Rica, Mexico, United States, and Uruguay) [32]. In an additional 18 member 
states (15 of which are in the Americas), IPV was recommended for children at increased 
risk of VAPP, including immunocompromised children [32]. IPV use is expected to increase 
as countries implement WHO recommendations for the polio endgame strategy [33].
With the introduction of a sequential IPV-OPV polio vaccination schedule, Brazil’s National 
Immunization Program initiated plans for IPV use following worldwide eradication of polio, 
when only IPV use will be recommended [34]. Introduction of IPV in Brazil’s National 
Immunization Program also meets updated recommendations from WHO’s Strategic 
Advisory Group of Experts in November 2012 that all countries introduce at least 1 dose of 
IPV in routine infant immunization schedules prior to withdrawal of type-2 OPV virus from 
trivalent OPV to mitigate risks of poliomyelitis associated with type-2 VDPVs [35].
Several considerations were important for the choice of a sequential IPV-OPV schedule in 
Brazil’s National Immunization Program. Despite limited experience with sequential IPV-
OPV schedules for routine infant immunizations in Latin America [15], experiences from 
the United States and countries in other regions have demonstrated success in maintaining 
elimination of wild poliovirus and preventing VAPP [29]. Several other Latin American 
countries, including Costa Rica and Mexico, have maintained national polio immunization 
days with OPV following an IPV-only routine infant immunization schedule [29], as 
recommended by PAHO [2]. In Brazil, the decision to maintain 1 NID with OPV was based 
on reducing risk of poliovirus transmission in the event of a WPV or VDPV importation and 
maintaining annual outreach activities to difficult-to-access populations during campaigns. 
Financial sustainability of IPV introduction was also considered in the context of increased 
government commitment to the national immunization program with the introduction of new 
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childhood vaccines in the past decade, including oral rotavirus vaccine, and pneumococcal 
and meningococcal serogroup C conjugate vaccines [20]. Finally, IPV introduction in Brazil 
contributes to equitable access to recommended vaccines among all Brazilian children, in 
accordance with the founding principles of Brazil’s national immunization program [3, 19].
Interpretation of immunization coverage and AFP surveillance data from Brazil is subject to 
several limitations. Declining reporting rates of VAPP since certification of polio 
elimination likely reflect underreporting of AFP cases [22, 23, 36]; incidence of VAPP in 
Brazil, while still rare, was believed to be higher than reported. Administrative coverage 
estimates are based on numbers of doses administered rather than children vaccinated, and 
municipal estimates of coverage are unreliable because doses are recorded by health center 
rather than place of residence. Brazil’s national immunization program has initiated a 
national immunization registry to provide more reliable immunization coverage data [20]. 
Data from immunization coverage surveys were only available for selected urban 
populations [19]. Concerns about heterogeneous polio immunization coverage and pockets 
of susceptible populations, especially in rural areas with conditions favorable to poliovirus 
transmission, motivated maintenance of 2 OPV doses in the routine polio immunization 
schedule and continuation of 1 annual polio immunization day for children aged <5 years.
With the international purchase of IPV, Brazil’s Ministry of Health launched an initiative 
with 3 national vaccine manufacturers—Bio-Manguinhos Institute of the Oswaldo Cruz 
Foundation in Rio de Janeiro, Butantan Institute in São Paulo, and Ezequiel Dias Foundation 
in Belo Horizonte—to produce a heptavalent vaccine for the national immunization 
program, containing diphtheria, tetanus, pertussis, Hib, HepB, IPV, and meningococcal 
serogroup C conjugate antigens. Availability of a nationally produced combination product 
containing IPV would reduce the number of vaccination visits and injections, and potentially 
reduce medical waste. In addition, production of combination vaccines in single-dose vials 
can reduce vaccine wastage without substantially increasing requirements for cold storage 
capacity. Brazil’s national immunization program continually works to expand access to 
safe and effective vaccines for all Brazilian children.
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A, Municipalities reporting <95% or ≥95% coverage with 3 doses of oral polio vaccine 
(OPV3) among children aged <1 year, January–December, 2011. B, Municipalities reporting 
<95% or ≥95% coverage (based on monthly target population) with 1 dose of inactivated 
polio vaccine (IPV1) among children aged <1 year, September–December, 2012.
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Table 1
Selected Revisions of Recommended Childhood Immunization Schedule in Brazil’s National Immunization 
Program, 1973–2012
Year Milestone
1973 Creation of National Immunization Program (recommended immunizations: BCG, OPV, measles, DTwP, smallpox)
1980 Polio Elimination Plan—2 national polio immunization days (OPV)
1986 Sustainability and National Self-Sufficiency Initiative (production of DTwP by national vaccine manufacturers)
1989 HepB vaccine campaigns in high-risk areas
1990 Established goals for 90% routine vaccination coverage (OPV, DTwP) and 95% coverage for OPV campaigns and measles 
vaccination
Multivaccination in National Immunization Days (all recommended vaccines)
1992 Measles elimination plan (measles 2nd dose)
Universal infant immunization against HepB
1992–2000 Phased introduction of MMR vaccine
1994 Yellow fever vaccination in high-risk areas incorporated into National Immunization Program
1995–2000 Rubella control strategy (measles-rubella or MMR campaigns, targeting persons aged 1–11 y in most states)
1999 Introduction of Hib conjugate vaccine
2002 Quadrivalent DTwP-Hib replaces DTwP and monovalent Hib conjugate vaccine
2006 Introduction of oral rotavirus vaccine (Human reassortment vaccine)
2010 Introduction of pneumococcal conjugate vaccine (10-valent)
Introduction of MenC conjugate vaccine
2012 Sequential IPV-OPV vaccination schedule for polio
Pentavalent DTwP-Hib-HepB replaces DTwP-Hib and HepB vaccines for infant vaccination
Abbreviations: BCG, Bacillus Calmette–Guérin; HepB, hepatitis B; Hib, Haemophilus influenzae type b; DTwP, diphtheria-tetanus-pertussis 
(whole cell); IPV, inactivated polio vaccine; MenC, meningococcal serogroup C; MMR, measles-mumps-rubella; OPV, oral polio vaccine.
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Table 5
Polio Immunization Schedule for Children Who Have Already Received 1 OPV Dose and for Children for 
Whom OPV Is Not Recommended, National Immunization Program, Brazil, 2012
Child’s Age and Prior Vaccination Status Polio Vaccination Note
At least 2-months of age, received ≥1 dose of OPV Complete series with OPV Children who begin schedule with OPV may 
continue with OPV only
At least 2 mo of age, received 1 dose of OPV between 
birth and 60 d of life
Begin sequential IPV-OPV 
series
OPV doses administered from birth to 60 d of life 
are not counted for the primary series
Age <12 mo, previously unvaccinated against polio Begin sequential IPV-OPV 
series
Previously unvaccinated children ≥12 mo may 
initiate polio vaccination series with OPV
Child with medical indication to receive IPV at 
CRIEa
IPV only series Sequential IPV-OPV schedule not recommended
Source: National Immunization Program, Ministry of Health, Brasília, Brazil.
Abbreviations: IPV, inactivated polio vaccine; OPV, oral polio vaccine; CRIE, Special Immunobiological Reference Center.
a
Acronym for name in Portuguese: Centro de Referência para Imunobiologicos Especiais.
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Table 6
Number of First and Second Doses of IPV Administered in Brazil’s National Immunization Program, as a 
Percentage of Monthly Target Population,a Brazil, August–December, 2012
Calendar Month
No. of IPV Doses Reported (% of Target)
1st dose 2nd dose
August 102 784 (43) 12 019 (5)
September 173 554 (72) 25 955 (11)
October 205 153 (85) 89 761 (37)
November 204 333 (85) 159 099 (66)
December 187 902 (78) 160 480 (67)
Abbreviation: IPV, inactivated polio vaccine.
a
Monthly target population = 240 006 children aged <1 year (1/12th of registered live births in 2011 from national live birth registration system 
[SINASC].).
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